

Alpha 2C Adrenergic Receptor - Pipeline Review, H1 2020

<https://marketpublishers.com/r/AAB00F1FEAD2EN.html>

Date: June 2020

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: AAB00F1FEAD2EN

Abstracts

Alpha 2C Adrenergic Receptor - Pipeline Review, H1 2020

SUMMARY

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) – Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. This receptor plays a critical role in regulating neurotransmitter release from sympathetic nerves and from adrenergic neurons in the central nervous system.

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) pipeline Target constitutes close to 5 molecules. The molecules developed by companies in Phase III, Phase II and Phase I stages are 1, 1 and 3 respectively. Report covers products from therapy areas Central Nervous System which include indications Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Disorders, Dementia Associated With Alzheimer's Disease, Depression, Generalized Anxiety Disorder (GAD), Major Depressive Disorder, Pervasive Developmental Disorder (PDD), Post-Traumatic Stress Disorder (PTSD) and Psychiatric Disorders.

The latest report Alpha 2C Adrenergic Receptor – Pipeline Review, H1 2020, outlays comprehensive information on the Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players

involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

The report reviews Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics and enlists all their major and minor projects

The report assesses Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Overview

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Companies Involved in Therapeutics Development

Avineuro Pharmaceuticals Inc

Denovo Biopharma LLC

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

SK Biopharmaceuticals Co Ltd

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Drug Profiles

apomorphine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AVN-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexipiprazole - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brexipiprazole LAI - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DB-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-PSY - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Dormant Products

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Discontinued Products

Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indication, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Avineuro Pharmaceuticals Inc, H1 2020

Pipeline by Denovo Biopharma LLC, H1 2020

Pipeline by Otsuka Holdings Co Ltd, H1 2020

Pipeline by Otsuka Pharmaceutical Co Ltd, H1 2020

Pipeline by SK Biopharmaceuticals Co Ltd, H1 2020

Dormant Projects, H1 2020

Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

COMPANIES MENTIONED

Avineuro Pharmaceuticals Inc

Denovo Biopharma LLC

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

SK Biopharmaceuticals Co Ltd

I would like to order

Product name: Alpha 2C Adrenergic Receptor - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/AAB00F1FEAD2EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAB00F1FEAD2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970